A µ-opioid receptor agonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

DAMGO (trifluoroacetate salt)

Item No. 21553

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Nα-methyl-L-phenylalaninamide, 2,2,2-trifluoroacetate
Synonyms
  • [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin
  • DAGO
  • NIH 10891
  • RX-783006
Molecular Formula
C26H35N5O6 • XCF3COOH
Formula Weight
513.6
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 30 mg/mlPBS (pH 7.2): 5 mg/ml
SMILES
OC1=CC=C(C[C@H](N)C(N[C@H](C)C(NCC(N(C)[C@H](C(NCCO)=O)CC2=CC=CC=C2)=O)=O)=O)C=C1.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C26H35N5O6.C2HF3O2/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18;3-2(4,5)1(6)7/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36);(H,6,7)/t17-,21+,22+;/m1./s1
InChi Key
NIGIQPUQVVEMTD-NJUGUJQKSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $55

    Add

    5 mg

    $143

    Add

    10 mg

    $203

    Add

    25 mg

    $402

    Add
    Product Description

    DAMGO is a selective peptide agonist of the µ-opioid receptor (Kis = 1.18, 1,430, and 213 nM for human µ-, δ-, and κ-opioid receptors, respectively).1,2 DAMGO displays higher efficacy than morphine (Item No. ISO60147) for µ-opioid-induced nociception in rats.3,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hirning, L.D., Mosberg, H.I., Hurst, R., et al. Studies in vitro with ICI 174,864, [D-Pen2, D-Pen5]-enkephalin (DPDPE) and [D-Ala2, NMePhe4, Gly-ol]-enkephalin (DAGO). Neuropeptides 5(4-6), 383-386 (1985).

    2. Zhao, G.-M., Qian, X., Schiller, P.W., et al. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at μ, δ, and κ opioid receptors. J. Pharmacol. Exp. Ther. 307(3), 947-954 (2003).

    3. Fang, F.G., Haws, C.M., Drasner, K., et al. Opioid peptides (DAGO-enkephalin, dynorphin A(1-13), BAM 22P) microinjected into the rat brainstem: Comparison of their antinociceptive effect and their effect on neuronal firing in the rostral ventromedial medulla. Brain Res. 501(1), 116-128 (1989).

    4. Kelly, E. Efficacy and ligand bias at the μ-opioid receptor. Br. J. Pharmacol. 169(7), 1430-1446 (2013).

    Product Citations

    Khan, S., Tyson, A.S., Ranjbar, M., et al. Structural snapshots capture nucleotide release at the μ-opioid receptor. Nature (2025).

    Malcolm, N.J., Palkovic, B., Sprague, D.J., et al. Mu-opioid receptor selective superagonists produce prolonged respiratory depression. iScience 26(7), 107121 (2023).

    Gomez, J.L., Ventriglia, E.N., Frangos, Z.J., et al. A µ-opioid receptor superagonist analgesic with minimal adverse effects. Nature 652(8112), 1393-1404 (2026).